GILD


Gilead To Pay $97M To Settle Kickback Debacle Over Letairis Drug

Gilead has agreed to pay $97 million to settle claims that it violated the False Claims Act by using a charitable foundation to …

Gilead Sciences Close To Inking $20B Immunomedics Deal- Report

Gilead Sciences (GILD) is nearing a deal to buy biotech Immunomedics Inc for more than $20 billion, says the Wall Street Journal, which …

Dr. Reddy’s Rolls Out Remdesivir For Covid-19 Treatment In India

Dr. Reddy’s Laboratories along with its subsidiaries announced the launch of Gilead Sciences coronavirus drug candidate remdesivir under the brand name Redyx in …

Gilead Submits Expanded Application For Yescarta Cancer Treatment

Gilead’s (GILD) Kite has announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S.

Gilead’s Remdesivir Now Authorized For All Hospitalized Covid-19 Patients

Gilead Science’s (GILD) investigational antiviral Veklury (remdesivir) has now received expanded Emergency Use Authorization (EUA) from the FDA to treat all hospitalized patients …

Gilead Says FDA Could Broaden Remdesivir Use Despite Data; Analyst Slashes PT

Gilead Sciences Inc. could be granted additional emergency use authorization by US regulators for its drug remdesivir to include patients hospitalized with moderate …

Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application

Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S.

Gilead ‘Very Pleased’ With Tango Collab, Boosts Cancer Targets To 15

Gilead Sciences (GILD) and Tango Therapeutics have announced an expanded collaboration focusing on targeted immune evasion therapies for cancer patients. Under the deal, …

Gilead Submits New Drug Application With FDA For Remdesivir

Gilead Sciences Inc. announced on Monday that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) …

Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment

Pfizer Inc. announced a multi-year agreement with Gilead Sciences, Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts